Drug name - Hetlioz Lq

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(2 months from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

CN1152679C VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

CN1239886A VANDA PHARMS INC Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents
Dec, 2017

(4 years ago)

EP1027043B1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A1 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

EP1027043A4 VANDA PHARMS INC Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents
Dec, 2017

(4 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders May, 2034

(11 years from now)

US11141400 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US10610511 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US10376487 VANDA PHARMS INC Method of treatment Jul, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment Aug, 2035

(12 years from now)

US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof Dec, 2040

(18 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.